- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
Younger Patients, Select Subsets in AML May Have Higher Chances of Long-Term Survival
January 09, 2021
Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.
Minimal Efficacy Observed With Eprenetapopt Plus Azacitidine in TP53-Mutant MDS
January 05, 2021
Treatment with the combination of eprenetapopt and azacitidine did not improve complete responses in patients with TP53-mutant myelodysplastic syndromes.
Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome
January 02, 2021
In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications
December 26, 2020
Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.
Pevonedistat/Azacitidine Combo Demonstrates Encouraging EFS Data in Phase 2 Trial in MDS
December 24, 2020
Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.
Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies
December 23, 2020
Experts in oncology and hematology review some of the most impactful FDA approvals from 2020 in lung, breast, blood, gastrointestinal, and genitourinary cancers.
FDA Updates Prescribing Label for Ibrutinib for Waldenström Macroglobulinemia Indication
December 23, 2020
The FDA updated the prescribing label for the approval of ibrutinib to include efficacy and safety data as combination therapy with rituximab as treatment of patients with Waldenström’s macroglobulinemia.
CD123-Targeting ADC IMGN632 Demonstrates Encouraging Findings in Rare Blood Cancer
December 23, 2020
The novel CD123-targeting antibody-drug conjugate IMGN632 demonstrated promising clinical activity in a cohort of heavily pretreated patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and had a favorable tolerability.
ASH 2020 Updates: Improving Outcomes in TIE-NDMM
December 23, 2020
Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.